Cancer Type: All Aim: To study/catalog the types of complementary (alternative) medicine (“CAM”) among patients at Maimonides, in an effort to increase understanding and possibly establish a CAM program at Maimonides.
Cancer Type: Pancreatic Aim: To determine if a drug (erlotinib) along with chemo-radiation can improve outcomes for patients with pancreatic cancer.
Cancer Type: Lung Aim: To find if adding the study drug, nivolumab (also known as OPDIVO®) will limit lung cancer from growing back in patients with early-stage non-small cell lung cancer.
Cancer Type: Lung Aim: To compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI®) after completion of surgery, and in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer.
Cancer Type: Lung Aim: To compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatment plus erlotinib (an investigational drug), which targets the EGFR mutation.
Cancer Type: Lung Aim: To examine lung cancer patients’ surgically removed tumors for certain genetic changes, and possibly refer patients to a treatment study that may specifically target tumors that have these genetic changes.
Cancer Type: Rectal Aim: To see if radiation can be avoided for a select group of rectal cancer patients who have a good response to 6 treatments with a chemotherapy combination regimen known as FOLFOX.
Cancer Type: Breast Aim: To study women who have cancer cells in the lymph nodes at the time that breast cancer is diagnosed and have chemotherapy before surgery that clears the cancer cells from the lymph nodes.
Cancer Type: Bladder A Phase III Randomized Adjuvant Study of MK-3475 (Pembrolizumab) In Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR).
This registry assesses patients undergoing initial (primary) endovascular repair of an AAA where the investigator believes the proximal aortic neck is challenging such that the risk of failure or fixation and/or sealing is great enough that the use of the Heli-FX EndoAnchor System is warranted.